Get the Stockscreener App
5.20
2.80%
-0.15
After Hours:
5.32
0.12
+2.31%
Cingulate Inc stock is traded at $5.20, with a volume of 465.91K.
It is down -2.80% in the last 24 hours and down -40.16% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$5.35
Open:
$5.38
24h Volume:
465.91K
Relative Volume:
0.99
Market Cap:
$60.47M
Revenue:
-
Net Income/Loss:
$-22.21M
P/E Ratio:
-1.1953
EPS:
-4.3505
Net Cash Flow:
$-17.41M
1W Performance:
-11.11%
1M Performance:
-40.16%
6M Performance:
+30.00%
1Y Performance:
+20.09%
1-Day Range:
$5.1051
$5.62
1-Week Range:
$5.1051
$6.13
52-Week Range:
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.20 | 62.21M | 0 | -22.21M | -17.41M | -4.3505 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
[S-3] Cingulate Inc. Shelf Registration Statement - Stock Titan
Research Analysts Issue Forecasts for Cingulate Q1 Earnings - MarketBeat
Quarterly Risk: Can Cingulate Inc Equity Warrant maintain its current growth rateEarnings Recap Report & Safe Capital Allocation Plans - baoquankhu1.vn
CING Should I Buy - Intellectia AI
Market Fear: Is Cingulate Inc likely to announce a buybackTrade Entry Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 - TMX Newsfile
Energy Moves: Is Cingulate Inc likely to announce a buyback2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Cingulate says its ADHD drug faces manufacturing review, not safety issues - Stock Titan
CING SEC FilingsCingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cingulate Adds Independent Director Jiang to Board Committees - The Globe and Mail
Cingulate appoints Zhanpeng Jiang to board of directors and key committees - Investing.com Australia
Cingulate Appoints Zhanpeng Jiang to Board of Directors - National Today
Cingulate appoints Zhanpeng Jiang to board of directors and key committees By Investing.com - Investing.com South Africa
Zhanpeng Jiang joins Cingulate (CING) board with option for 15,000 shares - Stock Titan
Revenue Check: Can Cingulate Inc Equity Warrant sustain earnings growth2026 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Revenue Check: Is Cingulate Inc Equity Warrants ROE strong enough2026 Sector Review & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Earnings Miss: Can Cingulate Inc Equity Warrant maintain its current growth rate2026 AllTime Highs & Weekly Setup with High ROI Potential - baoquankhu1.vn
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst - MSN
What's Going On With Cingulate Stock Today? - Dailyhunt
Cingulate (CING) registers 3.5M shares for Lincoln Park under $25M equity line - stocktitan.net
Falcon Creek discloses 28.5% Cingulate (CING) ownership stake - Stock Titan
Wall Street Recap: What is the target price for Cingulate Inc Equity Warrant stockMarket Trend Summary & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
FOMO Trade: Is Cingulate Inc currently under institutional pressureMarket Trend Report & Smart Money Movement Tracker - baoquankhu1.vn
Cingulate Announces ATM Equity Program and Share Issuance - The Globe and Mail
Cingulate Inc. Enters ATM Sales Agreement with A.G.P./Alliance Global Partners for Common Stock Offering – March 2026 - Minichart
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan
Can Cingulate Inc Equity Warrant sustain earnings growthWeekly Trade Review & Trade Opportunity Analysis - baoquankhu1.vn
Cingulate Inc has submitted a prospectus supplement to the U.S. Securities and Exchange Commission, planning to conduct a market offering and sell common shares in phases for a total amount of up to 100 million dollars. - Bitget
Cingulate (NASDAQ: CING) adds $100M ATM share sale capacity - Stock Titan
Cingulate Inc. (NASDAQ: CING) launches up to $100M ATM sales program - Stock Titan
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Roth Capital Lowers Price Target for Cingulate (CING) to $14, Ma - GuruFocus
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00 - marketbeat.com
Cingulate (NASDAQ: CING) files S-3/A amendment adding KPMG consent - Stock Titan
Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst - Dailyhunt
If You Invested $1,000 in Cingulate Inc (CING) - Stock Titan
History Review: Is Cingulate Inc likely to announce a buyback2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - MSN
What's going on with Cingulate stock today? - MSN
Stock Report: How cyclical is Cingulate Inc Equity Warrants revenue stream2026 Valuation Update & Long Hold Capital Preservation Plans - baoquankhu1.vn
CING: Laying the Foundation for 1H:27 Launch - Research Tree
3.5M-share resale registration by Cingulate (NASDAQ: CING) under Lincoln Park deal - Stock Titan
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress - Minichart
Cingulate (CING) Expected to Announce Earnings on Thursday - MarketBeat
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Bitget
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. Advances Precision Timed Release ADHD and Anxiety Treatments with Innovative Drug Delivery Platform – 2025 Annual Report Highlights - Minichart
Cingulate (CING) outlines CTx-1301 FDA review, ADHD market and PTR pipeline - Stock Titan
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):